Mirati Seeks Differentiation, Amgen Invests In Combos To Dominate KRAS G12C Field
Biomarker Data Confirm Amgen Strategy; Mirati’s Drug Works In CNS
Amgen outlined the most frequent co-mutations in treatment-resistant lung and colorectal cancers at ASCO, while Mirati’s adagrasib showed efficacy in active CNS metastases in lung cancer patients.
